Cross-sectional and longitudinal follow-up of changes in carbohydrate metabolism in prepubertal GH-treated SGA-patients: trends and variability; results of an unicentric study

Carmen Sydlik, Susanne Bechtold, Claudia Weizenbacher, Julia Roeb, Matthias Buckl, Stefanie Putzker, Heinrich Schmidt
Children’s Hospital of Ludwigs-Maximilians-University, Munich, Germany

Conclusion:
In our collective of growth hormone (GH)-treated prepubertal SGA-patients, we found continuously raising insulin resistance until at least 4 years of GH-treatment. 30-min-values always were the highest. HOMA and ISI can deteriorate independently of each other, thus follow-up of fasting glucose and insulin levels is not sufficient. Neither baseline nor 1-year-data for HOMA, ISI and/or OGTT are of prognostic value for further development of glucose tolerance during GH-therapy. In our collective, temporarily pathologic values had no therapeutic consequence.

Background / Aims:
Several studies show impaired glucose tolerance at a certain number of years after start of GH in SGA-children. The aim of our investigation was to perform a longitudinal and cross-sectional evaluation of OGTTs (glucose-insulin-pairs) in prepubertal GH-treated SGA-children of our clinic, to evaluate if ISI and HOMA are effective surrogates for glucose tolerance and if results of OGTT and the indices before and after the first year of treatment are of prognostic value.

Methods:
In 86 prepubertal SGA-born children older than 4 years OGTTs (glucose and insulin at 0, 30, 60 and 120 minutes) and HOMA as well as ISI were determined before start of GH and yearly under treatment until start of puberty or max. 4 years of treatment.

Results:
- For mean glucose-levels, there were no relevant changes before and during the first 4 years of treatment. Insulin-levels significantly increased with maximum values between 1 and 3 years with little reduction thereafter. Mean glucose/insulin-ratio almost continuously decreased. Highest values for glucose as well as insulin were seen at 30 min in all years (not represented in ISI). HbA1c was constant during all the years (5,3 +/- 0,64 to 5,4 +/- 0,24 %).
- HOMA-indices continuously increased during the years of treatment (0,83 +/- 0,83 to 1,53 +/- 0,98). As expected, ISI showed an almost inverse correlation to HOMA with decrease from 0 to 4 years (16,1 +/- 10,6 to 6,3 +/- 1,3). Yet, for both indices, mean values did not reach pathologic levels (HOMA > 2,5, ISI < 5).
- 3 of 81 children showed 0-min-glucose values > 100 mg/dl indicating impaired fasting glucose (IFG) even before GH-treatment, 7 of 81 120-min-values > 140 mg/dl (impaired glucose tolerance, IGT) and 3 elevated fasting insulin (> 10 µU/ml). None of them had pathologic OGTTs later. Only 4 of 81 had pathologic HOMA and/or ISI at baseline.
- After 1 year, 7 of 72 patients showed IFG, 2 had IGT and 5 high fasting insulin. 5 children showed elevated HOMA and 8 decreased ISI (mostly not the same as at 0 years). 9 of 59 children followed for > 1 year with any abnormal value before changed to normal. 16 of 59 with completely normal tests at 0 and 1 year showed at least one pathologic value later.

<table>
<thead>
<tr>
<th>Year</th>
<th>Glc 0min</th>
<th>Glc 30min</th>
<th>Glc 60min</th>
<th>Insulin 0min</th>
<th>Insulin 30min</th>
<th>Insulin 60min</th>
<th>Insulin 120min</th>
<th>Glc/Ins 0min</th>
<th>Glc/Ins 30min</th>
<th>Glc/Ins 60min</th>
<th>Glc/Ins 120min</th>
<th>HOMA</th>
<th>ISI</th>
<th>HbA1c</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>82</td>
<td>153</td>
<td>127</td>
<td>102</td>
<td>4,1</td>
<td>37,6</td>
<td>29,8</td>
<td>20,1</td>
<td>36,35</td>
<td>6,04</td>
<td>0,91</td>
<td>0,83</td>
<td>0,36</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>85</td>
<td>152</td>
<td>126</td>
<td>105</td>
<td>5,6</td>
<td>59,3</td>
<td>43,1</td>
<td>34,4</td>
<td>21,82</td>
<td>3,90</td>
<td>0,53</td>
<td>0,53</td>
<td>0,35</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>82</td>
<td>152</td>
<td>116</td>
<td>101</td>
<td>7,8</td>
<td>68,7</td>
<td>39,6</td>
<td>31,4</td>
<td>14,49</td>
<td>3,00</td>
<td>0,88</td>
<td>0,57</td>
<td>0,59</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>84</td>
<td>153</td>
<td>125</td>
<td>101</td>
<td>6,7</td>
<td>61,8</td>
<td>46,4</td>
<td>39,4</td>
<td>14,58</td>
<td>3,23</td>
<td>0,83</td>
<td>0,53</td>
<td>0,35</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>84</td>
<td>152</td>
<td>114</td>
<td>94</td>
<td>7,5</td>
<td>58,9</td>
<td>53,9</td>
<td>36,0</td>
<td>13,94</td>
<td>3,25</td>
<td>0,83</td>
<td>0,53</td>
<td>0,35</td>
<td></td>
</tr>
</tbody>
</table>

Mean values for glucose (Glc), insulin, ratio glucose/insulin (Glc/Ins) for all time points of OGTT, HOMA, ISI and HbA1c for baseline (0) and years of treatment 1 to 4

Poster presented at: Poster Session Online

DOI: 10.3252/pso.eu.54espe.2015